Protocol 10601, A phase 1 study of mosunetuzumab with polatuzumab vedotin and lenalidomide (M+Pola+Len) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

UVA Tracking #
301211
Principal Investigator
Emily Ayers
Contact
Contact Phone
Official Trial Title
A phase 1 study of mosunetuzumab with polatuzumab vedotin and lenalidomide (M+Pola+Len) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have diffuse large B-cell lymphoma. The purpose of this study is to test the safety of 3 drugs taken in combination called lenalidomide, mosunetuzumab, and polatuzumab vedotin. This study tests different doses of these drugs to identify the highest dose that is still safe for people. There are two parts in this study, a dose escalation part and a dose expansion part. Your doctor will tell you which part you are in. In the dose escalation part of this study, different people will get different doses of the study drug lenalidomide, but everyone will receive the same doses of the other study drugs mosunetuzumab and polatuzumab vedotin. In the dose expansion part of this study, the highest dose with manageable side effects will be given to up to 18 more people. This will help study doctors better understand the side effects that may happen with this drug. You will get lenalidomide as a pill you take by mouth on days 1 through 21 of each cycle, mosunetuzumab through a vein in the arm weekly on days 1, 8, and 15 of cycle 1 and then the first day of each proceeding cycle for 17 cycles, and polatuzumab vedotin through a vein in the arm on the first day of each cycle for 6 cycles. Each cycle lasts 28 days.

You are expected to be in this research study for about 6 years.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/study/NCT06015880

uvacancertrials@hscmail.mcc.virginia.edu

Compensation

No Compensation